BETA
Your AI-Trained Oncology Knowledge Connection!
Sabrina Serani is the assistant managing editor for Targeted Oncology.
NEO-MEL-T Study: Mooradian Explores TIM-3/PD-1 in Resectable Melanoma
Mirvetuximab Active in Platinum-Sensitive Ovarian Cancer Regardless of HRD Status
New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ovarian cancer, regardless of HRD status.
Zanzalintinib/Atezolizumab Improves CRC Survival, Expands TKI's Role in Solid Tumors
New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, marking a breakthrough in treatment options.
Pirtobrutinib Outperforms Standard Options in Relapsed/Refractory CLL/SLL
Pirtobrutinib shows significant benefits in progression-free survival and tolerability for relapsed CLL patients compared to standard treatments.
Mismatched Unrelated Donors and PTCy: Better HSCT Outcomes, Expanded Access
A groundbreaking trial shows promising survival rates and low GVHD in patients receiving mismatched stem cell transplants, expanding treatment options for diverse populations.
The Targeted Pulse: A Weekly Dose of Oncology Updates
This week in oncology highlights: FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.
Atezolizumab Efficacy in Cervical Cancer Consistent Irrespective of PD-L1
Adjuvant Pembrolizumab in Kidney Cancer: Dr Haas on KEYNOTE-564
Epcoritamab/R-ICE Shows High Response in R/R DLBCL, Aids ASCT Eligibility
Unveiling the Unseen: The Future of Posttreatment Cancer Detection
Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.
CID-078 Receives FDA Orphan Drug Designation in Small Cell Lung Cancer
Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform
A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.
Liso-Cel Demonstrates Deep, Durable Responses in R/R Marginal Zone Lymphoma
Lisocabtagene maraleucel led to promising responses in relapsed/refractory marginal zone lymphoma, offering a new option with manageable safety.
The Targeted Pulse: This Week in Review
Catch up on the week's latest oncology news, from clinical trial updates to FDA approvals.
Taletrectinib: A New Advance in ROS1-Mutant NSCLC
Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.
FDA Approves Zanubrutinib Tablet for All Indications
The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for patients with blood cancers.
FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer
Taletrectinib gains FDA approval as a groundbreaking treatment for ROS1-positive non-small cell lung cancer, offering hope for patients with CNS involvement.
Advancing Head and Neck Cancer Treatment: Insights From KEYNOTE-689
A groundbreaking trial explores pembrolizumab's role in enhancing treatment outcomes for advanced head and neck cancer, promising significant advancements in patient care.
FDA Grants Priority Review for Lurbinectedin/Atezolizumab in ES-SCLC
FDA prioritizes review of lurbinectedin and atezolizumab for first-line maintenance therapy in extensive-stage small cell lung cancer, promising improved survival rates.
FDA Lifts Partial Clinical Hold on IFx-2.0 Phase 3 Trial for Merkel Cell Carcinoma
TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response alongside pembrolizumab.
T-DXd to Be Explored in HER2-Expressing Advanced Endometrial Cancer
Uncovering Social Disparities in Early-Onset Colorectal Cancer
A recent study reveals rising early-onset colorectal cancer rates, highlighting disparities and the need for improved screening and early detection strategies.
The Targeted Pulse: Key Approvals, Regulatory Shifts, and ASCO Highlights
Pembrolizumab Sets New Standard in Advanced Cervical Cancer Care
Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for underserved women globally.
FDA Receives Vepdegestrant NDA for ESR1-Mutated Breast Cancer
A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing promising trial results.
Zipalertinib Offers Promising Oral Option for EGFR Exon 20+ NSCLC
Zipalertinib shows promising efficacy and safety for advanced NSCLC with EGFR exon 20 mutations, offering a much-needed oral treatment option.
Insights From VERIFY: Rusfertide Shows Promise in Polycythemia Vera
A groundbreaking study reveals rusfertide's potential to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient quality of life.
FDA Approves Darolutamide in Metastatic Castration-Sensitive Prostate Cancer
Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic castration-sensitive prostate cancer.
Darolutamide Improves Quality of Life in Metastatic Prostate Cancer
Darolutamide significantly delayed pain progression and improved overall well-being in patients with metastatic hormone-sensitive prostate cancer.
Rusfertide Shines as New Treatment Option in Polycythemia Vera
In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy in the space.